W. J. Classi- cation of Gastrointestinal Tract, 6th Edition.
Reading File
Finding Sources
Searching the Web
W.J. classification gastrointestinal tract 6th edition textbook
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC13128328
Searching PubMed
"WHO classification" AND "digestive system" AND "6th edition"
Your query appears to refer to the WHO Classification of Tumours of the Digestive System, 6th Edition (2026) - the "W. J." in your message is likely a formatting artifact (truncated "WHO"). Here is a detailed overview based on the latest published review (Arends et al., Histopathology, 2026 - PMID 41724188):
WHO Classification of Tumours of the Digestive System - 6th Edition (2026)
Overview
The 6th Edition represents a major update to the 5th edition. It integrates pathological, molecular, and clinical insights to refine the taxonomy of digestive system neoplasms, with continued emphasis on standardisation of terminology, coding, and diagnostic criteria for global consistency.
Structural Reorganisation
The book is reorganised into chapters as follows:
- Epithelial tumours - described by anatomical site (oesophagus, stomach, small intestine, colorectum, liver, biliary tract, pancreas, etc.)
- Neuroendocrine neoplasms - now gathered into a dedicated separate chapter (previously described organ by organ in the 5th edition), allowing greater alignment across the digestive system and with other organ systems
- Mesenchymal tumours - dedicated chapter, harmonised with the 6th edition WHO Soft Tissue Tumours classification
- Haematolymphoid tumours - dedicated chapter, aligned with other WHO volumes
- Genetic tumour syndromes - classified by mechanism, pathway, syndrome, and gene(s)
- Other tumours / Carcinoma of Unknown Primary (CUP) - CUP included for the first time in a separate section, classified by molecular and immunophenotypic profiles
Key Diagnostic Refinements by Site
| Site | Update |
|---|---|
| Oesophagus | New entity: oesophageal epidermoid metaplasia |
| Stomach | Consolidation of gastric dysplasia entities |
| Duodenum / Ampulla | Separated from jejuno-ileal tumours into distinct categories |
| Colorectum | Clearer categorisation of serrated polyps; novel carcinoma grading; new entity: colorectal intramucosal adenocarcinoma |
| Colorectum (new) | Low-grade tubuloglandular adenocarcinoma and lymphoglandular complex-like adenocarcinoma introduced |
| Liver | Sonic hedgehog hepatocellular adenoma introduced as new subtype |
| Bile ducts | Small- and large-duct intrahepatic cholangiocarcinoma as separate entities; new intraductal tubulopapillary and intraductal oncocytic papillary neoplasms |
| Pancreas | Updated entity definitions |
| Anal canal | Terminology harmonised with HPV-related LAST (Lower Anogenital Squamous Terminology) |
Major Conceptual Changes
1. Grading simplification
- Grading systems simplified to two-tier (low grade / high grade) across precursor lesions throughout the GI tract
- Enhanced criteria for neuroendocrine tumour (NET) grading
2. Undifferentiated carcinoma redefined
- "Carcinoma with sarcomatoid components" (5th edition term) replaced by "carcinoma with mesenchymal differentiation"
- A new subset defined: carcinomas with SWI/SNF chromatin remodelling complex deficiencies (somatic alterations in ARID1A, SMARCA2/BRM, SMARCA4/BRG1, SMARCB1/INI-1)
3. Mixed neuroendocrine/non-neuroendocrine neoplasms (MiNEN)
- Concept broadened to include tumours with dual neuroendocrine-non-neuroendocrine differentiation, now distinguished more clearly from MiNEN
4. Mesenchymal tumours
- SDH-deficient GIST introduced as a separate section - a distinctive neoplasm subtype, strongly syndromic, driven by mitochondrial complex 2 dysfunction
- NUT-rearranged sarcoma added as a new entity
- Harmonisation with ISSVA vascular anomaly classification for vascular neoplasms
5. Neuroendocrine tumours - new entity
- Type 4 ATP4A mutation-associated enterochromaffin-like (ECL) cell gastric NET - associated with severe hypergastrinemia from inactivating ATP4A mutations
Summary of Goals
The 6th Edition strengthens:
- Tumour diagnostic precision
- Molecular alignment across the digestive system
- Standardisation of terminology and coding for global clinical, research, and epidemiological use
The key review paper summarising all changes is:
- Arends MJ et al. "Changes in the 6th edition of the World Health Organization classification of tumours of the digestive system." Histopathology, June 2026. PMID 41724188
If you were referring to a different book (e.g., "Physiology of the Gastrointestinal Tract, 6th Edition" by Said), please let me know and I can provide information on that instead.
Relation of leiomyosarcoma and phyllodes
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
I now have comprehensive information from multiple authoritative surgical and pathology textbooks. Here is the full picture:
Relation of Leiomyosarcoma and Phyllodes Tumor
1. Shared Classification - Fibroepithelial / Mesenchymal Origin
Both leiomyosarcoma and phyllodes tumor are mesenchymal neoplasms of the breast. Phyllodes tumor arises specifically from the intralobular stroma, while leiomyosarcoma arises from the interlobular stroma (smooth muscle elements of breast vasculature or nipple).
- Robbins Pathologic Basis of Disease, p. 11 (Block)
2. Leiomyosarcoma as a Sarcomatous Type Arising in the Breast
Leiomyosarcoma is one of several histological types within the primary breast sarcoma group. This group includes:
- Fibrosarcoma
- Malignant fibrous histiocytoma
- Liposarcoma
- Leiomyosarcoma
- Malignant schwannoma
- Rhabdomyosarcoma
- Osteogenic sarcoma
- Chondrosarcoma
All present as large, painless, rapidly growing breast masses. Diagnosis requires core-needle biopsy or incisional biopsy. Treatment is wide local excision; axillary dissection is NOT indicated unless biopsy-proven nodal involvement is present.
- Schwartz's Principles of Surgery, 11th Ed., p. 1455
3. The Key Relationship - Malignant Phyllodes Undergoing Stromal/Sarcomatous Transformation
The most direct relationship between the two is that malignant phyllodes tumors can undergo sarcomatous transformation of their stroma. When this happens, the stromal component becomes indistinguishable from a frank sarcoma.
Key points from the textbooks:
- Malignant phyllodes tumors are widely infiltrative and "may be difficult to distinguish from sarcoma, particularly when there is marked stromal overgrowth with few residual epithelial elements" - Robbins
- The sarcomatous elements that most commonly arise in malignant phyllodes are liposarcomatous or rhabdomyosarcomatous, rather than fibrosarcomatous
- Leiomyosarcoma is one of the possible heterologous sarcomatous elements that can arise within malignant phyllodes, though it is among the less common compared to liposarcoma/rhabdomyosarcoma
- Schwartz's Principles of Surgery, 11th Ed., p. 1406
4. Distinguishing Malignant Phyllodes from Primary Sarcoma
| Feature | Malignant Phyllodes | Primary Breast Sarcoma (e.g., Leiomyosarcoma) |
|---|---|---|
| Epithelial component | Present (biphasic) | Absent |
| Stromal origin | Intralobular | Interlobular |
| Metastasis route | Hematogenous (lungs) | Hematogenous |
| Nodal spread | Very rare (axillary dissection contraindicated) | Rare |
| Metastatic content | Only stromal component metastasizes | Sarcoma cells |
| Grading | Benign / Borderline / Malignant | Based on cellularity, atypia, mitoses |
- Robbins Pathologic Basis of Disease, p. 363-364
- Sabiston Textbook of Surgery, p. 2392
5. Genetics / Syndromic Association
Both phyllodes tumor and leiomyosarcoma are associated with Li-Fraumeni syndrome (germline TP53 mutations). Phyllodes tumor additionally carries mutations in MED12, RARA, TERT, and RB.
- Sabiston Textbook, Cancer Genetics chapter (PMID referenced block)
Summary
The key relationship is:
Malignant phyllodes tumor is a fibroepithelial neoplasm whose malignant stromal component can undergo sarcomatous transformation, producing heterologous sarcomatous elements - including leiomyosarcoma, liposarcoma, rhabdomyosarcoma, and others. When stromal overgrowth is extreme and the epithelial component disappears, malignant phyllodes becomes virtually indistinguishable from a pure breast sarcoma such as leiomyosarcoma. Both neoplasms are treated with wide local excision and share the same routes of metastasis (hematogenous, primarily to the lung), without axillary nodal staging.
This is a shared conversation. Sign in to Orris to start your own chat.